Extracellular vesicles in pulmonary hypertension: lessons from mesenchymal stromal cell-derived exosomes
2019; American Physical Society; Volume: 316; Issue: 5 Linguagem: Inglês
10.1152/ajplung.00107.2019
ISSN1522-1504
AutoresJenny L. Hewes, Natalie Bauer,
Tópico(s)MicroRNA in disease regulation
ResumoEditorial FocusExtracellular vesicles in pulmonary hypertension: lessons from mesenchymal stromal cell-derived exosomesJenny L. Hewes and Natalie N. BauerJenny L. HewesDepartment of Pharmacology, Center for Lung Biology, University of South Alabama, Mobile, Alabama and Natalie N. BauerDepartment of Pharmacology, Center for Lung Biology, University of South Alabama, Mobile, AlabamaPublished Online:17 Apr 2019https://doi.org/10.1152/ajplung.00107.2019This is the final version - click for previous versionMoreSectionsPDF (63 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInWeChat Hogan et al. (6) investigated the central hypothesis that the smallest of the extracellular vesicle family, the exosome, could repair injured pulmonary vessels and pulmonary artery smooth muscle cells (PASMCs). Treatment of hypoxic PASMCs with exosomes isolated from primary human bone marrow-derived mesenchymal stem cells (MSC) improved amino acid metabolism and prevented the shift to glycolysis. Furthermore, intravenous injection of the isolated exosomes prevented hypoxic pulmonary hypertension (PH) in the mouse model and partially reversed it in the semaxinib/hypoxia rat model (6). This paper contributes to a wider body of literature on the nature of MSC-derived exosomes and their ability to repair vascular injury. In 2016, Aliotta et al. (1) described the ability of MSC-derived exosomes to prevent and even rescue the mouse monocrotaline model of PH. Further, Lee et al. (9) revealed that early intervention in hypoxia-induced PH in mice with MSC-derived exosomes prevented the influx of macrophages and repressed the activation of signal transducer and activator of transcription 3. These examples highlight the varied mechanisms by which MSC-derived exosomes might protect or heal vessels. However, several questions remain: 1) what is the nature of the exosomes and how do they relate to extracellular vesicles, in general; 2) what is the mechanism of action of exosomes and extracellular vesicles; and 3) are extracellular vesicles (including exosomes) truly reparative or injurious?Since the first descriptions of the effects of “platelet dust” on coagulation as early as 1967, there has been little consensus over how to define or characterize extracellular vesicles; however, great strides have been made in recent years (18). The minimal requirements for defining extracellular vesicles and their primary classes such as exosomes, microvesicles/microparticles, and apoptotic bodies were recently published by the International Society of Extracellular Vesicles (16). In less than a decade since the society was formed, in essence to tackle this issue of defining vesicles, there has been an explosion of literature and interest. Current dogma is that the defining characteristics of an exosome include having a diameter less than 1 μm, generally in the 100- to 200-nm range, and expression of protein markers such as CD63, CD81, TSG01, and ALIX. The work described by Hogan et al. (6) to characterize their functional vesicle is excellent. They provided the reader with a comprehensive view including the marker subsets, transmission electron microscopy, and the concentration and size of vesicles via nanoparticle tracking analysis. This is currently the expectation for publication; however, as new data emerge, more refinement of the definitions of extracellular vesicles may be on the horizon. Each of the protein markers defining exosomes was originally thought to delineate a vesicle, small in size, that was formed in the multivesicular body and released extracellularly. However, in 2016, Kowal et al. (8) identified CD63 and CD9 on the membrane of microvesicles (MVs). MVs are larger in diameter than exosomes and thought to be derived from the cellular plasma membrane. Thus, many publications are using the more encompassing title of extracellular vesicles (7, 15). This highlights an important area in the field of extracellular vesicle research, biogenesis. While some of the mechanisms for extracellular vesicle generation are well-defined, e.g., exosome formation through multivesicular body transport, others are not and include intracellular calcium regulation of the cytoskeleton, alterations in membrane symmetry, and mechanical perturbation (5, 10, 11). Each of these mechanisms will no doubt influence the intravesicle and membrane contents including proteins and RNA. Thus, this area of investigation could yield valuable insight into how we can further manipulate extracellular vesicles, and their tiniest counterpart the exosome, into biological therapeutics and, importantly, how we might also prevent the release of detrimental extracellular vesicles.Decades of work have shown that MSC infusions are beneficial for pulmonary vasculopathy, but later work determined that merely the conditioned medium, and not the cells themselves, was sufficient for repair. It has now become clear that a factor in that medium, the isolated extracellular vesicle or exosome, is a primary functioning component. Lee et al. (9) elegantly illustrated that MSC-derived exosome-depleted media did not prevent hypoxic PH, nor did fibroblast-derived exosomes. Inflammatory cell infiltration is a hallmark of pulmonary vascular lesion formation, and MSC-derived exosomes blocked macrophage infiltration. Hogan et al. (6) highlight this with their work, indicating that even a single dose of intravenous MSC-derived exosomes prevented hypoxic PH and that repeated dosing reversed the more robust semaxinib/hypoxia rat model of PH. Hogan et al. examined the exosomes directly, using proteomics and RNAseq to guide their investigations and found metabolic programming as a potential mechanism. MSC-derived exosomes in the hands of Hogan et al., clearly inhibit the hypoxic activation of sirtuin 4, releasing glutamate dehydrogenase-1, and pyruvate dehydrogenase to drive metabolism and improve mitochondrial function. However, Aliotta et al. (1) also examined MSC-derived exosomes directly and their data suggest that a miRNA component of the exosome drives repair. Use of MSC-derived exosomes for repair is not limited to the pulmonary vasculature, but also tracheal instillation reduces hyperoxia-induced damage in a rat model of bronchopulmonary dysplasia (14). These data demonstrate the complexity of extracellular vesicle signaling. Whether the exosomes (or other extracellular vesicles) themselves have pleiotropic effects, whether the starting material and method of stimulation alters the exosome contents, or whether the mechanisms used by the recipient cells to make use of extracellular vesicle contents differ are all questions that will drive the field forward.While there is mounting evidence that MSC-derived exosomes can generally be considered “good”, during disease many extracellular vesicles deliver injurious messages such as alterations in nitric oxide signaling and stimulation of inflammatory molecules on the endothelium (2, 4, 17). Microparticles (MPs) in particular, especially those with phosphatidylserine on their membrane, are frequently reported to induce injury in a variety of lung diseases including PH, acute lung injury, and cigarette smoking-induced damage. So, how might we tip the balance between “good” and “bad” extracellular vesicles? Mohning et al. (12) examined clearance mechanisms of MPs by alveolar macrophages and determine phosphatidylserine-positive MPs were cleared by the phosphatidylserine-binding MerTK receptors expressed on resident macrophages. While inducing clearance of dangerous MPs is an attractive concept, not all injurious extracellular vesicles express phosphatidylserine; therefore, future studies into alternative clearance mechanisms would benefit the field as a whole. In an effort to maximize the potential for “good” exosomes to deliver their message, Zhang et al. (19) have provided a novel methodology to enrich microRNAs (miRNAs) in isolated exosomes for delivery to recipient cells. Prior work to enrich miRNAs in exosomes focused on upregulating the miRNA in parent cells; however, the novelty of Zhang’s method is direct enrichment in the isolated exosome. As we continue to understand the constituents of circulating and cell culture-derived extracellular vesicles, it is intriguing to envision a time when we can manipulate the vesicles to our benefit, either inhibiting the “bad” ones or enriching the “good” ones, to restore homeostasis.The work by Hogan et al. (6) provides direct evidence of mitochondrial repair in PASMCs, and further, the contents of the MSC-derived exosomes includes metabolism-associated genes and proteins. However, we still do not fully understand how extracellular vesicles deliver their contents to recipient cells, otherwise known as the “endocytic problem”. Many studies have examined the interactions and uptake of labeled extracellular vesicles into recipient cells and tissues. The mechanisms involve the endocytic pathway and a variety of necessary cytoskeletal proteins (3, 5, 13). However, direct evidence of intracellular processing of the intact or even opened vesicle and its contents has not been determined. Future studies into intracellular processing of extracellular vesicles will significantly strengthen their potential as therapeutics and provide mechanisms to inhibit delivery of dangerous content.Severe PH is a devastating syndrome with no curative therapeutics, and current therapies have minimal effects on mortality. Therefore, the work described by Hogan et al. (6), investigating a novel mechanism of vessel and pulmonary vascular smooth muscle mitochondrial repair utilizing MSC-derived exosomes, is timely and important. While we clearly have many hurdles to overcome in our understanding of extracellular vesicle/exosome signaling, it is reasonable that study of these extracellular vesicles will provide novel insight into the pathology and potential treatment of PH.GRANTSThis work was supported in part by NIH National Heart, Lung, and Blood Institute Grants R01 HL133066 (N. N. Bauer) and T32 HL076125 (J. L. Hewes).DISCLOSURESNo conflicts of interest, financial or otherwise, are declared by the authors.AUTHOR CONTRIBUTIONSN.N.B. drafted manuscript; J.L.H. and N.N.B. edited and revised manuscript; J.L.H. and N.N.B. approved final version of manuscript.REFERENCES1. Aliotta JM, Pereira M, Wen S, Dooner MS, Del Tatto M, Papa E, Goldberg LR, Baird GL, Ventetuolo CE, Quesenberry PJ, Klinger JR. Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice. Cardiovasc Res 110: 319–330, 2016. doi:10.1093/cvr/cvw054. Crossref | PubMed | ISI | Google Scholar2. Blair LA, Haven AK, Bauer NN. Circulating microparticles in severe pulmonary arterial hypertension increase intercellular adhesion molecule-1 expression selectively in pulmonary artery endothelium. Respir Res 17: 133, 2016. doi:10.1186/s12931-016-0445-1. Crossref | PubMed | ISI | Google Scholar3. Costa Verdera H, Gitz-Francois JJ, Schiffelers RM, Vader P. Cellular uptake of extracellular vesicles is mediated by clathrin-independent endocytosis and macropinocytosis. J Control Release 266: 100–108, 2017. doi:10.1016/j.jconrel.2017.09.019. Crossref | PubMed | ISI | Google Scholar4. Densmore JC, Signorino PR, Ou J, Hatoum OA, Rowe JJ, Shi Y, Kaul S, Jones DW, Sabina RE, Pritchard KA Jr, Guice KS, Oldham KT. Endothelium-derived microparticles induce endothelial dysfunction and acute lung injury. Shock 26: 464–471, 2006. doi:10.1097/01.shk.0000228791.10550.36. Crossref | PubMed | ISI | Google Scholar5. Hargett LA, Bauer NN. On the origin of microparticles: From “platelet dust” to mediators of intercellular communication. Pulm Circ 3: 329–340, 2013. doi:10.4103/2045-8932.114760. Crossref | PubMed | ISI | Google Scholar6. Hogan SE, Rodriguez Salazar MP, Cheadle J, Glenn R, Medrano C, Petersen TH, Ilagan RM. Mesenchymal stromal cell-derived exosomes improve mitochondrial health in pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. In press. doi:10.1152/ajplung.00058.2018. Link | ISI | Google Scholar7. Juan T, Fürthauer M. Biogenesis and function of ESCRT-dependent extracellular vesicles. Semin Cell Dev Biol 74: 66–77, 2018. doi:10.1016/j.semcdb.2017.08.022. Crossref | PubMed | ISI | Google Scholar8. Kowal J, Arras G, Colombo M, Jouve M, Morath JP, Primdal-Bengtson B, Dingli F, Loew D, Tkach M, Théry C. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci USA 113: E968–E977, 2016. doi:10.1073/pnas.1521230113. Crossref | PubMed | ISI | Google Scholar9. Lee C, Mitsialis SA, Aslam M, Vitali SH, Vergadi E, Konstantinou G, Sdrimas K, Fernandez-Gonzalez A, Kourembanas S. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation 126: 2601–2611, 2012. doi:10.1161/CIRCULATIONAHA.112.114173. Crossref | PubMed | ISI | Google Scholar10. Letsiou E, Bauer N. Endothelial extracellular vesicles in pulmonary function and disease. Curr Top Membr 82: 197–256, 2018. doi:10.1016/bs.ctm.2018.09.002. Crossref | PubMed | ISI | Google Scholar11. McVey M, Tabuchi A, Kuebler WM. Microparticles and acute lung injury. Am J Physiol Lung Cell Mol Physiol 303: L364–L381, 2012. doi:10.1152/ajplung.00354.2011. Link | ISI | Google Scholar12. Mohning MP, Thomas SM, Barthel L, Mould KJ, McCubbrey AL, Frasch SC, Bratton DL, Henson PM, Janssen WJ. Phagocytosis of microparticles by alveolar macrophages during acute lung injury requires MerTK. Am J Physiol Lung Cell Mol Physiol 314: L69–L82, 2018. doi:10.1152/ajplung.00058.2017. Link | ISI | Google Scholar13. Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles 3: 24641, 2014. doi:10.3402/jev.v3.24641. Crossref | PubMed | Google Scholar14. Porzionato A, Zaramella P, Dedja A, Guidolin D, Van Wemmel K, Macchi V, Jurga M, Perilongo G, De Caro R, Baraldi E, Muraca M. Intratracheal administration of clinical-grade mesenchymal stem cell-derived extracellular vesicles reduces lung injury in a rat model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 316: L6–L19, 2019. doi:10.1152/ajplung.00109.2018. Link | ISI | Google Scholar15. Sayner SL, Choi CS, Maulucci ME, Kc R, Zhou C, Scruggs AK, Yarbrough T, Blair LAH, King JAC, Seifert R, Kaever V, Bauer NN. Extracellular vesicles: another compartment for the second messenger, cyclic adenosine monophosphate. Am J Physiol Lung Cell Mol Physiol.In press. doi:10.1152/ajplung.00282.2018. Link | ISI | Google Scholar16. Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin-Smith GK, Ayre DC, Bach JM, Bachurski D, Baharvand H, Balaj L, Baldacchino S, Bauer NN, Baxter AA, Bebawy M, Beckham C, Bedina Zavec A, Benmoussa A, Berardi AC, Bergese P, Bielska E, Blenkiron C, Bobis-Wozowicz S, Boilard E, Boireau W, Bongiovanni A, Borràs FE, Bosch S, Boulanger CM, Breakefield X, Breglio AM, Brennan MA, Brigstock DR, Brisson A, Broekman ML, Bromberg JF, Bryl-Górecka P, Buch S, Buck AH, Burger D, Busatto S, Buschmann D, Bussolati B, Buzás EI, Byrd JB, Camussi G, Carter DR, Caruso S, Chamley LW, Chang YT, Chen C, Chen S, Cheng L, Chin AR, Clayton A, Clerici SP, Cocks A, Cocucci E, Coffey RJ, Cordeiro-da-Silva A, Couch Y, Coumans FA, Coyle B, Crescitelli R, Criado MF, D’Souza-Schorey C, Das S, Datta Chaudhuri A, de Candia P, De Santana EF, De Wever O, Del Portillo HA, Demaret T, Deville S, Devitt A, Dhondt B, Di Vizio D, Dieterich LC, Dolo V, Dominguez Rubio AP, Dominici M, Dourado MR, Driedonks TA, Duarte FV, Duncan HM, Eichenberger RM, Ekström K, El Andaloussi S, Elie-Caille C, Erdbrügger U, Falcón-Pérez JM, Fatima F, Fish JE, Flores-Bellver M, Försönits A, Frelet-Barrand A, Fricke F, Fuhrmann G, Gabrielsson S, Gámez-Valero A, Gardiner C, Gärtner K, Gaudin R, Gho YS, Giebel B, Gilbert C, Gimona M, Giusti I, Goberdhan DC, Görgens A, Gorski SM, Greening DW, Gross JC, Gualerzi A, Gupta GN, Gustafson D, Handberg A, Haraszti RA, Harrison P, Hegyesi H, Hendrix A, Hill AF, Hochberg FH, Hoffmann KF, Holder B, Holthofer H, Hosseinkhani B, Hu G, Huang Y, Huber V, Hunt S, Ibrahim AG, Ikezu T, Inal JM, Isin M, Ivanova A, Jackson HK, Jacobsen S, Jay SM, Jayachandran M, Jenster G, Jiang L, Johnson SM, Jones JC, Jong A, Jovanovic-Talisman T, Jung S, Kalluri R, Kano SI, Kaur S, Kawamura Y, Keller ET, Khamari D, Khomyakova E, Khvorova A, Kierulf P, Kim KP, Kislinger T, Klingeborn M, Klinke DJ II, Kornek M, Kosanović MM, Kovács AF, Krämer-Albers EM, Krasemann S, Krause M, Kurochkin IV, Kusuma GD, Kuypers S, Laitinen S, Langevin SM, Languino LR, Lannigan J, Lässer C, Laurent LC, Lavieu G, Lázaro-Ibáñez E, Le Lay S, Lee MS, Lee YXF, Lemos DS, Lenassi M, Leszczynska A, Li IT, Liao K, Libregts SF, Ligeti E, Lim R, Lim SK, Linē A, Linnemannstöns K, Llorente A, Lombard CA, Lorenowicz MJ, Lörincz AM, Lötvall J, Lovett J, Lowry MC, Loyer X, Lu Q, Lukomska B, Lunavat TR, Maas SL, Malhi H, Marcilla A, Mariani J, Mariscal J, Martens-Uzunova ES, Martin-Jaular L, Martinez MC, Martins VR, Mathieu M, Mathivanan S, Maugeri M, McGinnis LK, McVey MJ, Meckes DG Jr, Meehan KL, Mertens I, Minciacchi VR, Möller A, Møller Jørgensen M, Morales-Kastresana A, Morhayim J, Mullier F, Muraca M, Musante L, Mussack V, Muth DC, Myburgh KH, Najrana T, Nawaz M, Nazarenko I, Nejsum P, Neri C, Neri T, Nieuwland R, Nimrichter L, Nolan JP, Nolte-’t Hoen EN, Noren Hooten N, O’Driscoll L, O’Grady T, O’Loghlen A, Ochiya T, Olivier M, Ortiz A, Ortiz LA, Osteikoetxea X, Østergaard O, Ostrowski M, Park J, Pegtel DM, Peinado H, Perut F, Pfaffl MW, Phinney DG, Pieters BC, Pink RC, Pisetsky DS, Pogge von Strandmann E, Polakovicova I, Poon IK, Powell BH, Prada I, Pulliam L, Quesenberry P, Radeghieri A, Raffai RL, Raimondo S, Rak J, Ramirez MI, Raposo G, Rayyan MS, Regev-Rudzki N, Ricklefs FL, Robbins PD, Roberts DD, Rodrigues SC, Rohde E, Rome S, Rouschop KM, Rughetti A, Russell AE, Saá P, Sahoo S, Salas-Huenuleo E, Sánchez C, Saugstad JA, Saul MJ, Schiffelers RM, Schneider R, Schøyen TH, Scott A, Shahaj E, Sharma S, Shatnyeva O, Shekari F, Shelke GV, Shetty AK, Shiba K, Siljander PR, Silva AM, Skowronek A, Snyder OL II, Soares RP, Sódar BW, Soekmadji C, Sotillo J, Stahl PD, Stoorvogel W, Stott SL, Strasser EF, Swift S, Tahara H, Tewari M, Timms K, Tiwari S, Tixeira R, Tkach M, Toh WS, Tomasini R, Torrecilhas AC, Tosar JP, Toxavidis V, Urbanelli L, Vader P, van Balkom BW, van der Grein SG, Van Deun J, van Herwijnen MJ, Van Keuren-Jensen K, van Niel G, van Royen ME, van Wijnen AJ, Vasconcelos MH, Vechetti IJ Jr, Veit TD, Vella LJ, Velot É, Verweij FJ, Vestad B, Viñas JL, Visnovitz T, Vukman KV, Wahlgren J, Watson DC, Wauben MH, Weaver A, Webber JP, Weber V, Wehman AM, Weiss DJ, Welsh JA, Wendt S, Wheelock AM, Wiener Z, Witte L, Wolfram J, Xagorari A, Xander P, Xu J, Yan X, Yáñez-Mó M, Yin H, Yuana Y, Zappulli V, Zarubova J, Žėkas V, Zhang JY, Zhao Z, Zheng L, Zheutlin AR, Zickler AM, Zimmermann P, Zivkovic AM, Zocco D, Zuba-Surma EK. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 7: 1535750, 2018. doi:10.1080/20013078.2018.1535750. Crossref | PubMed | ISI | Google Scholar17. Tual-Chalot S, Guibert C, Muller B, Savineau JP, Andriantsitohaina R, Martinez MC. Circulating microparticles from pulmonary hypertensive rats induce endothelial dysfunction. Am J Respir Crit Care Med 182: 261–268, 2010. doi:10.1164/rccm.200909-1347OC. Crossref | PubMed | ISI | Google Scholar18. Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 13: 269–288, 1967. doi:10.1111/j.1365-2141.1967.tb08741.x. Crossref | PubMed | ISI | Google Scholar19. Zhang D, Lee H, Zhu Z, Minhas JK, Jin Y. Enrichment of selective miRNAs in exosomes and delivery of exosomal miRNAs in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol 312: L110–L121, 2017. doi:10.1152/ajplung.00423.2016. Link | ISI | Google ScholarAUTHOR NOTESAddress for reprint requests and other correspondence: N. Bauer, Dept. of Pharmacology, Center for Lung Biology, College of Medicine, Univ. of South Alabama, Mobile, AL 36688 (e-mail: [email protected]edu). Download PDF Previous Back to Top Next FiguresReferencesRelatedInformation Related ArticlesMesenchymal stromal cell-derived exosomes improve mitochondrial health in pulmonary arterial hypertension 17 Apr 2019American Journal of Physiology-Lung Cellular and Molecular PhysiologyCited ByExtracellular vesicles in heart failure – A study in patients with heart failure with preserved ejection fraction or heart failure with reduced ejection fraction characteristics undergoing elective coronary artery bypass grafting18 October 2022 | Frontiers in Cardiovascular Medicine, Vol. 9Intratracheal administration of mesenchymal stem cell-derived extracellular vesicles reduces lung injuries in a chronic rat model of bronchopulmonary dysplasiaAndrea Porzionato, Patrizia Zaramella, Arben Dedja, Diego Guidolin, Luca Bonadies, Veronica Macchi, Michela Pozzobon, Marcin Jurga, Giorgio Perilongo, Raffaele De Caro, Eugenio Baraldi, and Maurizio Muraca28 April 2021 | American Journal of Physiology-Lung Cellular and Molecular Physiology, Vol. 320, No. 5 Press Release E-cigarette Use during Pregnancy Creates Lung Dysfunction in Babies - December 8, 2022 More from this issue > Volume 316Issue 5May 2019Pages L720-L722 Copyright & PermissionsCopyright © 2019 the American Physiological Societyhttps://doi.org/10.1152/ajplung.00107.2019PubMed30864818History Received 6 March 2019 Accepted 6 March 2019 Published online 17 April 2019 Published in print 1 May 2019 Metrics
Referência(s)